CAU Scholar's Space: Kang, Won Ku

Detailed Information

Kang, Won Ku (강원구)

약학대학 (약학부)

Research Area

Tel 02-820-5601
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Pharmacokinetics:11||Rat:8||LCMS/MS:7||HPLCMS/MS:5||pharmacokinetics:4||Rat plasma:4||Intravenous:3||Ilimaquinone:3||Caffeine:3||Drug interaction:3||Metaanalysis:3||7OSuccinyl macrolactin A:3||Bioavailability:2||ELFEMF:2||training project:2||Aceclofenac:2||panduratin A:2||Macrolactin A:2||Amisulpride:2||periodontitis:2||Toxicity:2||Regulatory science:2||Panduratin A:2||Metabolism:2||SGSP1:2||Pharmacokinetic modeling:2||Stability:2||Sulfisoxazole:2||Cyclosporine:1||Diacetyl sulfiaoxazole:1||Diallyl sulfide:1||Dienetichron plot:1||Dog plasma:1||Dosing regimen:1||Drug–drug interaction:1||Drug absorption:1||Drug metabolism:1||Duloxetine:1||Duration of therapy:1||ERK1/2:1||Epiilimaquinone:1||Etanercept:1||Extrapolation:1||Fc epsilon RI:1||Fenofibrate:1||FirstInMan dose:1||Food:1||Food effect:1||Gallic acid:1||Gastrointestinal system:1||Gender:1||Gut microbiota:1||HPLC:1||HPLC–MS/MS:1||HPLCMS:1||HPLCMSJMS:1||High concentration protein:1||High density lipoprotein:1||Highperformance liquid chromatography:1||Human:1||IL2:1||IL9:1||IMI:1||In vivo:1||Intragastric:1||Korean Red Ginseng (KRG):1||MAPK pathway:1||MFDS:1||MS:1||Mast cell:1||Mesupron:1||Metabolic activation:1||Metabolic syndrome:1||Mice:1||Mouse:1||N1acetyl sulfisoxazole:1||N4acetyl sulfisoxazole:1||NFkappa B:1||NFkappa B pathway:1||NONMEM:1||Neovascular agerelated macular degeneration:1||Obesity:1||Oleanolic acid:1||Orthotopolin riboside:1||PK/PD modeling:1||Parity:1||Pharmacodynamics:1||Plasma:1||Propolis:1||Protein microbead:1||Protein precipitation:1||Prothrombin time:1||Prunus persica L:1||Publication:1||Publication bias:1||Rabbit:1||Randomized controlled trials:1||Rats:1||Reporting:1||Rivaroxaban:1||Rutaecarpine:1||SGHQ2:1||Saturable pharmacokinetics:1||Shikimic acid:1||SimCYP:1||Skin:1||Solanum melongena:1||Stereoselective pharmacokinetics:1||Systematic review:1||Systemic exposure:1||T helper 9 cell:1||Thioacetamide:1||Three Nacetylated metabolites:1||Topical ocular:1||Trial registration:1||UV detection:1||Uridine:1||Verapamil:1||Wnt/betacatenin signaling:1||Wnt/βcatenin pathway:1||Xanthorrhizol:1||adverse reactions:1||allergic inflammation:1||allometric scaling:1||alveolar bone:1||anaphylaxis:1||antiinflammatory:1||antiinflammatory effect:1||antiperiodontitis:1||antioxidant:1||baicalein:1||baicalin:1||bilobetin:1||biological evaluation of dosage forms:1||caffeine:1||combination drug:1||controlled and sustainedrelease systems:1||costeffectiveness analysis:1||crossreactivity:1||cyclooxygenase:1||cytochrome P450:1||dehydration:1||disease progression model:1||dosage form design and characterization:1||drug compendia:1||drug development:1||drug interaction:1||drug monograph:1||drugdrug interaction (DDI):1||education and training:1||eggplant:1||fingerroot extracts:1||fluoxetine:1||gallic acid:1||gingival tissue:1||glial cells:1||glucocorticoids:1||high exposure group:1||human daily dose:1||hydrochlorothiazide:1||hypertension:1||in vivo:1||inflammation:1||inflammatory cytokine:1||innovative medicines initiative:1||interindividual variability:1||intestinal microbiota:1||intravenous:1||korean:1||macrophage:1||macrophages:1||mast cell:1||mast cells:1||mice:1||national health insurance:1||nitric oxide synthase:1||nonlinear mixed effect modeling:1||olmesartan medoxomil:1||osteoblastogenesis:1||osteoclastogenesis:1||p53 pathway:1||patient access:1||pediatrics:1||percutaneous absorption:1||periodontal inflammation:1||peroxiredoxin1:1||pharmaceutics and drug delivery:1||pharmacodynamics:1||physiologically based pharmacokinetics:1||population analysis:1||population pharmacokinetic:1||population pharmacokinetics:1||primary metabolites:1||proinflammatory cytokines:1||proinflammatory mediators:1||rat:1||regulatory science education:1||reimbursement:1||resveratrol:1||risksharing agreement:1||stalk:1||stem cell transplantation:1||sulfonamide allergy and hypersensitivity:1||sulfonamide medications:1||terpinyl acetate:1||3OAcetyloleanolic acid:1||vasoconstriction:1||4 'Hydroxydiclofenac:1||4 'Hydroxydiclofenac, Diclofenac:1||AMPK:1||Absolute bioavailability:1||Advanced breast cancer:1||Adverse drug reaction:1||Afloqualone:1||Allometric scaling:1||Ankylosing spondylitis:1||Apoptosis:1||Atopic dermatitis:1||BPE:1||Baicalein:1||Baicalin:1||Batsch:1||Boesenbergia pandurata Roxb.:1||Bone mineral density:1||Broussochalcone A:1||CGK012:1||CYP:1||CYP1A2:1||Chrysin:1||Clinical trials:1||Colon and liver cancers:1||Conjugated linoleic acid:1||Contrast media:1||Curcuma xanthorrhiza:1||

STATISTICS: Total View :6,818,683; Today View :710

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE